基准测试ChatGPT和其他大型语言模型用于慢性脏疾病的个性化特定阶段的饮食建议
Makpal Kairat1, Gulnoza Adilmetova1, Ilvira Ibraimova2
1Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Journal of clinical medicine
|November 27, 2025
概括
人工智能聊天机器人对慢性病 (CKD) 的饮食指导有希望. 双子座的表现最好,但人工智能工具在CKD营养中临床使用需要更多的验证.
科学领域:
- 人工智能在医学中的应用
- 临床营养学 临床营养学
- 脏营养学 脏营养学
背景情况:
- 慢性病 (CKD) 需要精确的饮食管理,根据阶段和个体患者需求而有所不同.
- 人工智能 (AI) 聊天机器人为CKD提供了产生饮食建议的潜力.
- 人工智能在CKD营养中的临床有效性和实际应用,尤其是在不同的环境中,需要进行彻底的调查.
研究的目的:
- 评估人工智能聊天机器人 (GPT-4,Gemini,Copilot) 的准确性,个性化性和实用性,用于生成CKD特定的饮食计划.
- 为了比较不同的人工智能模型在提供饮食建议方面的表现,与既定的临床指南进行比较.
主要方法:
- 模拟了不同阶段的CKD患者个人资料,用于提示三个AI聊天机器人进行饮食计划.
- 人工智能生成的饮食计划被医生评估为个性化,指导方针一致性,实用性和可用性,使用利克尔特尺度.
- 分析了饮食计划的营养含量,并与手动计算和临床饮食标准进行了比较.
主要成果:
- 与Copilot相比,双子座和GPT-4在个性化和指南一致性方面的得分明显更高.
- 在实用性方面,GPT-4在双子卫星上表现出了微不足道的优势.
- 营养分析揭示了AI估计的差异,特别是,和的差异,表明可能偏离临床建议.
结论:
- 人工智能聊天机器人,特别是双子座,显示出在CKD管理中协助饮食建议的潜力.
- 在CKD营养护理中广泛采用AI工具之前,进一步的研究,包括使用真实患者数据进行临床验证,至关重要.
- 人工智能驱动的饮食指导需要改进,以确保准确性,个性化和遵守有效的以患者为中心的护理的临床指南.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
326
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
175
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
175
01:25Chronic Kidney Disease I: Introduction
549
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
549
01:24Chronic Kidney Disease II: Clinical Manifestations
531
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
01:18Chronic Kidney Disease IV: Nursing Management
307
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
307
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
198
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
198